Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AYTU vs IBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AYTU Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

AYTU Overall Winner 6-Pillar Tally: AYTU 3 – 2 IBIO (1 Tie) Matrix Metrics: AYTU 6 – 4 IBIO

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over iBio, Inc. (IBIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas IBIO carries 46.0/100 (HOLD) at $0.72 (N/M Forward P/E, -3025.6% operating margin).

  • Growth vs. Quality Trade-Off: AYTU earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. IBIO 46.0/100 HOLD) and 0.65β · 35% Vol risk profile, whereas IBIO leads top-line expansion (+975.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile IBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AYTU vs IBIO
AYTU NASDAQ Head-to-Head Winner
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00
IBIO NASDAQ
iBio, Inc. Common Stock
Pharmaceutical Preparations
$0.72
-2.04% 1D
Market Cap $53.7M
TTM Revenue $1.1M
Forward P/E N/M
Beta / 30D Vol 2.07β · 89% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.5%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $0.78 · SMA50: $0.97

6-Pillar Scorecard Institutional Category Breakdown (AYTU 3 – 2 IBIO)

Columns: Metric · AYTU · IBIO
1. Valuation Multiples AYTU
Forward P/E 9.2x N/M
Trailing P/E 9.2x N/M
PEG Ratio N/M N/M
EV / Revenue 0.3x 7.8x
2. Growth & Scale IBIO
Revenue Growth (YoY) +6.4% +975.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $58M $1.1M
Market Cap $19.6M $53.7M
3. Profitability & Quality IBIO
Gross Margin 64.0% 100.0%
Operating Margin -14.4% -3025.6%
Net Profit Margin -24.8% 0.0%
Return on Equity (ROE) -52.5% -51.8%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$1.4M -$22M
Cash Flow Margin -2.4% N/A
Net Cash / Leverage $4.9M Net Cash $45M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 78.4% of Rev ($45M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AYTU (6) vs IBIO (4)
Institutional Metric AYTU IBIO Criterion Row Edge
Market Capitalization
Scale
$19.6M $53.7M Larger Scale IBIO
Trailing P/E Ratio
Valuation
9.2x N/M Lower Multiple AYTU
Forward P/E Ratio
Valuation
9.2x N/M Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+6.4% +975.0% Higher Growth IBIO
Operating Margin (TTM)
Profitability
-14.4% -3025.6% Higher Margin AYTU
Net Profit Margin
Profitability
-24.8% 0.0% Higher Margin IBIO
Return on Equity (ROE)
Capital Efficiency
-52.5% -51.8% Higher ROE IBIO
52-Week Range Position
Momentum
5% ($2–$3) 1% ($1–$4) Stronger Trend AYTU
Beta / 30D Volatility
Risk Regime
0.65β · 35% Vol 2.07β · 89% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 46.0 / 100 (HOLD) Higher Composite AYTU
Trailing 12M Revenue (USD)
Operating Scale
$58M $1.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 7.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($4.9M Net Cash) -$22M ($45M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBIO +4.81 pp
AYTU: -11.27% · IBIO: -6.46%
3M Horizon AYTU +27.26 pp
AYTU: -23.31% · IBIO: -50.57%
6M Horizon AYTU +35.71 pp
AYTU: -13.81% · IBIO: -49.52%
1Y Horizon AYTU +25.53 pp
AYTU: -12.14% · IBIO: -37.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AYTU Revenue IBIO Revenue AYTU Op. Margin IBIO Op. Margin Margin Leader
FY2019 $10M $0M -230.1% -782.4% AYTU
FY2020 $30M $0M -76.5% -854.9% AYTU
FY2021 $70M $0M -89.7% -1312.1% AYTU
FY2022 $100M $0M -113.7% -1576.3% AYTU
FY2023 $110M N/A -15.9% N/A AYTU
FY2024 $70M $0M -2.4% -7392.9% AYTU
FY2025 $70M $0M -11.8% -4650.5% AYTU
FY2026 $60M $0M -14.4% -35141.0% AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published
IBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $53.7M market capitalization and -3025.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AYTU vs IBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over iBio, Inc. (IBIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas IBIO carries 46.0/100 (HOLD) at $0.72 (N/M Forward P/E, -3025.6% operating margin). Growth vs. Quality Trade-Off: AYTU earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. IBIO 46.0/100 HOLD) and 0.65β · 35% Vol risk profile, whereas IBIO leads top-line expansion (+975.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile IBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBIO leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with IBIO at +975.0% YoY revenue growth and +0.0% YoY earnings growth on $1.1M TTM revenue (100.0% gross margin, -3025.6% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while IBIO shifted N/A. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBIO.

AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas IBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus IBIO (-51.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, IBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 89% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.